E. Molinari

发表

Pharmacology of human sulphonylurea receptor SUR1 and inward rectifier K+ channel Kir6.2 combination expressed in HEK‐293 cells

J. Sullivan, J. Brioni, C. Shieh, 2000, British journal of pharmacology.

Characterization of the ATP-sensitive potassium channels (KATP) expressed in guinea pig bladder smooth muscle cells.

J. Sullivan, J. Brioni, C. Shieh, 1999, The Journal of pharmacology and experimental therapeutics.

Pharmacological and molecular characterization of ATP-sensitive K+ channels in the TE671 human medulloblastoma cell line.

J. Brioni, M. Gopalakrishnan, L. Monteggia, 1999, European journal of pharmacology.

[125I]A-312110, a novel high-affinity 1,4-dihydropyridine ATP-sensitive K+ channel opener: characterization and pharmacology of binding.

G. Gintant, C. Shieh, M. Gopalakrishnan, 2003, Molecular pharmacology.

Characterization and modulation of [125I]iberiotoxin-D19Y/Y36F binding in the guinea-pig urinary bladder.

J. Brioni, M. Gopalakrishnan, J. Sullivan, 2000, European journal of pharmacology.

Regulation of Human α4β2 Neuronal Nicotinic Acetylcholine Receptors by Cholinergic Channel Ligands and Second Messenger Pathways

J. Sullivan, M. Gopalakrishnan, E. Molinari, 1997 .

2-[125I]iodo-5-methoxycarbonylamino-N-acetyltryptamine: a selective radioligand for the characterization of melatonin ML2 binding sites.

M. Dubocovich, E. Molinari, P. C. North, 1996, European journal of pharmacology.

Regulation of human alpha4beta2 neuronal nicotinic acetylcholine receptors by cholinergic channel ligands and second messenger pathways.

J. Sullivan, M. Gopalakrishnan, E. Molinari, 1997, Molecular pharmacology.

Characterization of a novel ATP‐sensitive K+ channel opener, A‐251179, on urinary bladder relaxation and cystometric parameters

J. Brioni, C. Shieh, Y. Kurachi, 2007, British journal of pharmacology.

Pharmacological characterization of a 1,4‐dihydropyridine analogue, 9‐(3,4‐dichlorophenyl)‐3,3,6,6‐tetramethyl‐3,4,6,7,9,10‐hexahydro‐1,8(2H,5H)‐acridinedione (A‐184209) as a novel KATP channel inhibitor

J. Sullivan, M. Gopalakrishnan, S. Buckner, 2003, British journal of pharmacology.

The high affinity melationin binding site probed with conformationally restricted ligand--I. Pharmacophore and minireceptor models.

J. Jansen, M. Dubocovich, J M Jansen, 1996, Bioorganic & medicinal chemistry.

ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A potent and selective cholinergic channel modulator with neuroprotective properties.

D. Donnelly-roberts, D. Mckenna, S. Arneric, 1997, The Journal of pharmacology and experimental therapeutics.

(−)-(9S)-9-(3-Bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-Dioxide (A-278637): A Novel ATP-Sensitive Potassium Channel Opener Efficacious in Suppressing Urinary Bladder Contractions. I. In Vitro Characterization

J. Sullivan, R. Chess-Williams, M. Williams, 2002, Journal of Pharmacology and Experimental Therapeutics.

Stable expression, pharmacologic properties and regulation of the human neuronal nicotinic acetylcholine alpha 4 beta 2 receptor.

D. Donnelly-roberts, S. Arneric, J. Sullivan, 1996, The Journal of pharmacology and experimental therapeutics.

Up-regulation of human alpha7 nicotinic receptors by chronic treatment with activator and antagonist ligands.

S. Arneric, J. Sullivan, M. Messi, 1998, European journal of pharmacology.

A-85380 [3-(2(S)-azetidinylmethoxy) pyridine]: in vitro pharmacological properties of a novel, high affinity alpha 4 beta 2 nicotinic acetylcholine receptor ligand.

D. Mckenna, S. Arneric, J. Sullivan, 1996, Neuropharmacology.